Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications

Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications Purpose of Review Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis are increasingly recognized as a key hallmark of cancer. Recent Findings The role of alterations in glutamine metabolism in pancreatic tumor progression has been elucidated in animal models and human cells lines, and there has been considerable interest in exploiting these aberrations for the treatment of pancreatic cancer. Other strategies targeting NQO1/GLS1 inhibition, NAD+ synthesis, and TCA cycle intermediates are being actively studied in the clinic. Summary Aberrant metabolism in pancreatic cancer poses a unique therapeutic strategy. We review preclinical and clinical studies looking to exploit alterations in the metabolic circuitry of pancreatic cancer. . . . . Keywords Pancreatic cancer Glutamine Anaplerosis NADPH-quinone oxidoreductase 1 ß-lapachone Abbreviations ROS Reactive oxygen species α-KG α-Ketoglutarate TCA Tricarboxylic acid cycle β-lap β-Lapchone BPTES Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2- yl)ethyl sulfide Introduction Gln Glutamine GlnI Glutamine synthase Pancreatic adenocarcinoma (PDAC) is a leading cause of Gls1 Glutaminase 1 cancer-related mortality in western countries. In the USA, Gls2 Glutaminase 2 there http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications

Current Oncology Reports , Volume 20 (7) – May 11, 2018

Loading next page...
 
/lp/springer_journal/pancreatic-cancer-metabolism-molecular-mechanisms-and-clinical-0AQf80S2gs
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
DOI
10.1007/s11912-018-0699-5
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis are increasingly recognized as a key hallmark of cancer. Recent Findings The role of alterations in glutamine metabolism in pancreatic tumor progression has been elucidated in animal models and human cells lines, and there has been considerable interest in exploiting these aberrations for the treatment of pancreatic cancer. Other strategies targeting NQO1/GLS1 inhibition, NAD+ synthesis, and TCA cycle intermediates are being actively studied in the clinic. Summary Aberrant metabolism in pancreatic cancer poses a unique therapeutic strategy. We review preclinical and clinical studies looking to exploit alterations in the metabolic circuitry of pancreatic cancer. . . . . Keywords Pancreatic cancer Glutamine Anaplerosis NADPH-quinone oxidoreductase 1 ß-lapachone Abbreviations ROS Reactive oxygen species α-KG α-Ketoglutarate TCA Tricarboxylic acid cycle β-lap β-Lapchone BPTES Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2- yl)ethyl sulfide Introduction Gln Glutamine GlnI Glutamine synthase Pancreatic adenocarcinoma (PDAC) is a leading cause of Gls1 Glutaminase 1 cancer-related mortality in western countries. In the USA, Gls2 Glutaminase 2 there

Journal

Current Oncology ReportsSpringer Journals

Published: May 11, 2018

References